Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227915 | 0.89 | ALDH1A1 (0.64) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E | |
| SCHEMBL30228241 | 0.86 | ALDH1A1 (0.57) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E | |
| SCHEMBL30231686 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HPGDMAPTKDM4EHSD17B10 | |
| SCHEMBL30227919 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E | |
| SCHEMBL30228191 | 0.80 | MAPT (0.55) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E | |
| SCHEMBL21629565 | 0.79 | ALDH1A1 (0.66) | ALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL5332450 | 0.78 | ALDH1A1 (0.78) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E | |
| SCHEMBL31711159 | 0.76 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E | |
| SCHEMBL30228279 | 0.76 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E | |
| SCHEMBL21629591 | 0.76 | ALDH1A1 (0.55) | ALDH1A1HPGDMAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023034346-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | ALDH1A1 3178/4885HPGD 2486/4885MAPT 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.